Those are the label's rules, and each has a measurement behind it: only about 1% to 2% of the semaglutide in a tablet is absorbed, and in the label's studies absorption was higher with less water and with a longer wait before eating. The dose rises every 30 days, from 1.5 mg to 4 mg, 9 mg and then 25 mg from day 91. In the 64-week trial, the 25 mg tablet reduced weight by 13.6% on average, against 2.4% on placebo. A missed tablet is skipped, not doubled.1
The routine, as the label writes it
The Wegovy prescribing information gives these instructions for the tablets.1
- Once a day, in the morning, on an empty stomach. Take one tablet orally once daily on an empty stomach in the morning.
- With water only, up to 4 ounces. Take it with water, up to 4 ounces. Do not take it with other liquids besides water.
- Whole. Swallow the tablet whole. Do not split, crush, chew or dissolve it in any solution.
- Then wait 30 minutes. After taking a tablet, wait at least 30 minutes before eating food, drinking beverages or taking other oral medications.
- One a day, no more. Do not take more than one tablet per day.
- Keep them dry. Store the tablets in a dry place away from moisture.
The patient leaflet puts the last step positively: after 30 minutes, you can eat, drink, or take other oral medicines.1 Four ounces is half a cup, about 120 milliliters.
Why each rule exists
The injection and the tablet deliver the same drug, semaglutide, by very different routes. After an injection under the skin, the label puts the share of the dose that reaches the blood at 89%. After a tablet, it estimates that share at approximately 1% to 2%.1 The tablets contain an absorption enhancer, salcaprozate sodium (SNAC). With so little of the dose absorbed, what is in the stomach when the tablet is swallowed matters, and that is what the label's studies measured.1
The label describes two studies in healthy volunteers that show what the water and the wait do.1
- Less water, more drug. Single tablets were taken with 50 mL or 240 mL of water after an 8-hour overnight fast, followed by 4 more hours without food. Absorption, measured both as total exposure and as peak level, was higher with 50 mL than with 240 mL.
- Up to 120 mL makes no difference. In a second study, people took a daily tablet for 10 days with 50 mL or 120 mL of water. The label found no difference in absorption between the two amounts that mattered clinically.
- A longer wait, more drug. The same study tested waits of 15, 30, 60 or 120 minutes before eating. Absorption was higher after a longer wait.
In the first of these studies, an empty stomach meant an 8-hour overnight fast. The label's instruction to take the tablet in the morning, before anything else, is the everyday version of that condition.1
So the label's 4 ounces is the tested upper end of the range that made no difference, and its 30 minutes is a minimum, not a target. Waiting longer than 30 minutes is allowed, and in the label's study a longer wait raised absorption.1
The tablet works quickly. The label puts the peak concentration of semaglutide at 1 hour after a tablet, against 1 to 3 days after an injection.1
The 30-minute minimum and the rule of water only, up to 4 ounces, are the label's. The label's study found higher absorption with a longer wait; it did not test any wait longer than 120 minutes.
The four dose steps
The tablet starts low and rises every 30 days, to reduce the risk of stomach and gut side effects.1
| Days | Daily tablet mg | Stage |
|---|---|---|
| 1 to 30 | 1.5 | Starting dose |
| 31 to 60 | 4 | Escalation |
| 61 to 90 | 9 | Escalation |
| 91 onward | 25 | Maintenance |
WEGOVY prescribing information, section 2.3, Table 2.1
In the tablet trial, the dose reached 25 mg after a 12-week escalation and then stayed there for a year.1 The label leaves room to slow down: if a dose is not tolerated during escalation, the prescriber can consider delaying the next step. And if the 25 mg maintenance dose is not tolerated, it suggests considering a switch to the Wegovy injection at 1.7 mg once a week.1
Dates follow the label's schedule of 30 days per step; a prescriber may hold a step longer. Prices are NovoCare's self-pay prices for one bottle of 30 tablets, read November 20, 2026, and may change.
Each step is a separate bottle. NovoCare's self-pay prices, read on November 20, 2026, are $149 for a month of 1.5 mg, $199 for 4 mg and $299 for 9 mg or 25 mg, with a month defined as one bottle of 30 tablets.2 Our page on what Wegovy costs compares the tablet with the pen over a year.
Who the tablet is for
Wegovy tablets are approved for adults, together with a reduced-calorie diet and more physical activity, for two uses: to reduce excess body weight and keep it off long term in adults with obesity, or with overweight and at least one weight-related condition, and to reduce the risk of major cardiovascular events, such as heart attack, stroke or cardiovascular death, in adults with established cardiovascular disease and obesity or overweight.1
The injection has two uses the tablet does not. The injection is also approved for teenagers aged 12 and older with obesity and for a form of fatty liver disease with fibrosis. The label states that the safety of the tablets has not been established in pediatric patients or in patients with that liver disease.1
The label lists two contraindications, the same for both forms: a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2, and a prior serious allergic reaction to semaglutide or to any ingredient of the injection or the tablet. Its limitations of use add that Wegovy should not be combined with other semaglutide products or other GLP-1 receptor agonists.1 In the tablet trial, 8% of participants were aged 65 to 74 and 2% were 75 or older.1
What the tablet did in its trial
The label's tablet trial, Study 7, enrolled adults with obesity, or overweight and at least one weight-related condition, and excluded people with type 2 diabetes. The tablet or a matching placebo was raised to 25 mg once a day over 12 weeks and then kept there for 52 weeks, 64 weeks in all, alongside counseling for a diet of about 500 fewer calories a day and at least 150 minutes of activity a week. It randomized 307 people, two to the tablet for every one to placebo. Their average age was 48, 79% were women, and they started at an average of about 106 kg with a body mass index of 38.1
| At week 64 | Placebo, 102 people | 25 mg tablet, 205 people |
|---|---|---|
| Average starting weight | 104.8 kg | 106.4 kg |
| Average change in body weight | −2.4% | −13.6% |
| Lost at least 5% | 31.3% | 76.3% |
| Lost at least 10% | 14.4% | 59.8% |
| Lost at least 15% | 5.5% | 47% |
| Lost at least 20% | 3.1% | 27.9% |
| Change in waist | −2.8 cm | −12.2 cm |
WEGOVY prescribing information, section 14.2, Tables 11 and 16. All randomized participants are included; body weight at week 64 was missing for 6.3% on the tablet and 11.8% on placebo.1
The pounds apply the trial's averages to the weight you enter. They describe the trial group and are not a prediction for one person; half of the people in a trial do better than the average and half do worse.
Fewer people stopped taking the tablet than the placebo: 18% against 25.5% stopped the study drug during the trial.1 The label also reports that waist size fell by 12.2 cm on the tablet and by 2.8 cm on placebo, and that systolic blood pressure fell by 7 mmHg against 5.4.1
The blood tests moved in the same direction, though less. Triglycerides fell by 18.1% on the tablet and 9.1% on placebo, LDL cholesterol by 2.9% against a rise of 0.2%, and HbA1c, in people without diabetes who started at 5.7%, by 0.3 points against 0.1. HDL cholesterol rose by 3.3% on the tablet and fell by 1.1% on placebo. Resting heart rate rose by 2.7 beats a minute on the tablet and 2.4 on placebo.1
How the tablet compares with the injection
The label's model predicts that, in people with overweight or obesity and no type 2 diabetes, the 25 mg daily tablet produces average semaglutide levels comparable to the 2.4 mg weekly injection: about 77 nmol/L against about 75. The difference is in the spread. In 90% of patients, average levels ranged from 27 to 186 nmol/L on the tablet and from 51 to 110 nmol/L on the injection.1 The tablet's daily absorption depends on the morning routine, which is one reason the levels vary more from person to person.
Levels in nmol/L from the label, for adults with overweight or obesity without type 2 diabetes. The range is the one within which 90% of patients' average levels fell.
For people with type 2 diabetes the picture differs. The label says the tablets have not been studied for weight reduction in adults with type 2 diabetes, and that in people with type 2 diabetes the average semaglutide levels on the 25 mg tablet were lower than on the 2.4 mg injection, possibly because less of the tablet is absorbed. For patients with type 2 diabetes who need more weight reduction on the 25 mg tablet, or who respond inadequately, it suggests considering the injection instead.1
Side by side, the two forms differ more in routine than in drug.1,2
| Wegovy tablet | Wegovy pen | |
|---|---|---|
| How often | Once a day | Once a week |
| When | In the morning, on an empty stomach | Any time of day, with or without meals |
| Food and drink | Water only, up to 4 oz, then 30 minutes before anything else | No restriction |
| Steps to maintenance | Every 30 days: 1.5, 4, 9, then 25 mg from day 91 | Every 4 weeks: 0.25, 0.5, 1, 1.7, then 2.4 mg from week 17 |
| A missed dose | Skip it, take the next one the following day | Take it if the next dose is more than 2 days away |
| Approved ages | Adults | Adults and children 12 and older |
| Absorbed share of the dose | About 1% to 2% | 89% |
| Self-pay at NovoCare, a month | $149, $199, then $299 | $349 for 0.25 to 2.4 mg |
WEGOVY prescribing information, sections 1, 2 and 12.3; NovoCare prices read November 20, 2026.1,2
Switching between the pen and the tablet
The label gives exact timing in both directions.1
- Pen to tablet. Adults on the 2.4 mg injection for weight reduction or cardiovascular risk reduction may switch to 25 mg tablets. Start the tablets one week after the last injection.
- Tablet to pen. Adults on 25 mg tablets may switch to the injection. Start the 2.4 mg weekly injection the day after the last tablet.
- If 25 mg is not tolerated. Consider switching to the 1.7 mg injection.
- Type 2 diabetes and more weight loss needed. Consider switching to the 1.7 mg injection and follow the injection's dose escalation.
The switch skips the tablet's escalation in both directions: the label moves people from 2.4 mg weekly straight to 25 mg daily, and back. Our page on the Wegovy dosing schedule covers the pen's steps.
A missed tablet
The rule is simpler than for the pen. If a tablet is missed, skip it and take the next dose the following day.1 Do not take two the next morning: the label says not to take more than one tablet per day.1
The label does not say what to do if a tablet was taken with food, coffee or too much water by mistake. It describes what happens to absorption in those conditions, as above, and it says one tablet a day at most. A morning that went wrong is a question for the pharmacist or prescriber, not a reason for a second tablet.
Side effects of the tablet
The label says that in the trial of the 25 mg tablet, the types and frequency of common adverse reactions were similar to those of the injection in its weight-reduction trials.1 For the injection, those were nausea in 44% against 16% on placebo, diarrhea in 30% against 16%, vomiting and constipation in 24% each, and abdominal pain in 20%.1 The tablet-specific numbers the label gives:
| In the tablet trial | Placebo | 25 mg tablet |
|---|---|---|
| Stopped because of any adverse reaction | 5.9% | 6.9% |
| Stopped because of a stomach or gut reaction | 2% | 3.4% |
| Severe stomach or gut reaction | 0% | 2% |
| Altered skin sensations, such as burning, tingling or sensitive skin (dysesthesia) | 0% | 5% |
WEGOVY prescribing information, sections 5.6 and 6.1. Section 14 of the same label gives 6.8% for stopping because of an adverse reaction.1
The warnings on the label apply to both forms: a boxed warning about thyroid C-cell tumors seen in rodents, then pancreatitis, gallbladder disease, low blood sugar in people with diabetes, kidney injury from fluid loss, severe stomach reactions, allergic reactions, diabetic eye complications, a raised heart rate, and aspiration during anesthesia.1 As with the injection, the label says the tablets are not recommended in people with severe gastroparesis.1 Our page on Wegovy side effects covers when they peak and how long they last.
The label's warning on low blood sugar applies too. Wegovy lowers blood glucose and can cause hypoglycemia, and the risk is higher in people with type 2 diabetes who also take insulin or a sulfonylurea.1 The tablet has not been studied for weight reduction in people with type 2 diabetes, so for them the injection's trial data are the closer guide.1
Other pills and the 30 minutes
The wait applies to other oral medicines as well as to food: the label says to wait at least 30 minutes after the tablet before taking them.1 Beyond that timing, semaglutide slows the emptying of the stomach, so the label says it has the potential to affect the absorption of other medicines taken by mouth.1
One finding concerns the tablet specifically. In an interaction study with the semaglutide tablet, exposure to levothyroxine, the thyroid hormone, was 33% higher. The label asks prescribers to monitor the effects of oral medicines taken with Wegovy and to consider more monitoring for medicines that have a narrow therapeutic index or need clinical monitoring.1 Someone who takes levothyroxine, which is also usually taken on an empty stomach in the morning, has a reason to tell both prescribers.
For other medicines the label's study results were reassuring. It found no differences that mattered clinically in the levels of lisinopril, warfarin, metformin, digoxin, ethinyl estradiol, levonorgestrel, furosemide or rosuvastatin when taken with semaglutide, and omeprazole did not change the levels of semaglutide.1
The answers repeat the label's instructions for Wegovy tablets. They do not cover the injection, which can be taken with or without food at any time of day.
Coffee, tea and other drinks
The label is strict on two points. The tablet itself is taken with water only: "Do not take with other liquids besides water." And after the tablet, the wait of at least 30 minutes covers drinking beverages as well as eating.1 So morning coffee or tea comes at least 30 minutes after the tablet, and so does juice, milk or a protein shake.
The label does not name coffee specifically and does not measure what coffee does to absorption. What it does measure points one way: absorption was higher with less water at the moment of taking the tablet and higher with a longer wait afterwards.1
Pregnancy and breastfeeding
Two points are specific to the tablet.1
- Breastfeeding. The label advises not to breastfeed while taking the tablets. In a lactation study semaglutide in milk was below the level that could be measured, but SNAC, the absorption enhancer, and its breakdown products are present in human milk, and infants may clear SNAC more slowly than adults. The label notes that other forms of semaglutide without SNAC can be used during breastfeeding.
- Pregnancy. The label advises stopping Wegovy at least 2 months before a planned pregnancy because semaglutide is cleared slowly. It adds that in rats SNAC crossed the placenta and reached fetal tissues.
The label puts the time for semaglutide to leave the circulation at about 5 to 7 weeks after the last 25 mg tablet, the same as after the last injection.1
Short answers to common questions
When should I take the Wegovy pill?
In the morning, on an empty stomach, with up to 4 ounces of plain water, and at least 30 minutes before food, drinks or other pills.
Can I take it at night?
The label says to take it in the morning on an empty stomach. It gives no evening schedule.
Can I drink coffee after the Wegovy pill?
After at least 30 minutes. The label says to take the tablet with water only and to wait 30 minutes before drinking beverages.
What if I took it with too much water or ate too soon?
The label's studies found lower absorption with more water and with a shorter wait. It says to take no more than one tablet a day, so a second tablet is not the answer; ask the pharmacist or prescriber.
What if I took two tablets by mistake?
The label's overdose section says that overdoses of other GLP-1 medicines have caused severe nausea, severe vomiting and severe low blood sugar, that observation may need to be long because semaglutide is cleared slowly, and it gives the Poison Help line, 1-800-222-1222.
What if I miss a day?
Skip the missed tablet and take the next one the following day.
Can I cut or crush the tablet?
No. The label says to swallow it whole and not to split, crush, chew or dissolve it.
Is the pill as effective as the injection?
The label does not compare them directly. The 25 mg tablet reduced weight by 13.6% against 2.4% on placebo over 64 weeks, and the label predicts similar average semaglutide levels to the 2.4 mg injection in people without type 2 diabetes.
How do I switch from the pen to the pill?
Start 25 mg tablets one week after the last 2.4 mg injection. In the other direction, start the 2.4 mg injection the day after the last tablet.
Can I take it with my thyroid medicine?
Tell your prescriber first. In the label's study, exposure to levothyroxine was 33% higher when it was taken with the semaglutide tablet, and both are taken in the morning on an empty stomach.
Can I take the pill while breastfeeding?
The label advises against it, because SNAC, the absorption enhancer in the tablet, reaches breast milk. It notes that forms of semaglutide without SNAC can be used during breastfeeding.
Is the pill approved to protect the heart?
Yes. The label approves the tablets to reduce the risk of major cardiovascular events in adults with established cardiovascular disease and obesity or overweight, as well as for weight reduction.
How should I store the pills?
In a dry place away from moisture, according to the label.
How much does the pill cost?
At NovoCare's self-pay prices read November 20, 2026: $149 for a month of 1.5 mg, $199 for 4 mg and $299 for 9 mg or 25 mg.
How this page was built
Every instruction and number was read on November 20, 2026, in the current Wegovy prescribing information, which covers both the injection and the tablets: sections 2 (dosing, missed doses, switching), 6 (side effects), 7 (other medicines), 8 (pregnancy, breastfeeding, type 2 diabetes), 12.3 (absorption studies and levels) and 14 (the tablet trial). The prices come from NovoCare, read the same day. The morning planner and the dose calendar only apply the label's rules to the times and dates you enter.
The limits are these. The label's absorption studies were in healthy volunteers. The tablet trial excluded people with type 2 diabetes and did not compare the tablet with the injection directly. The label does not address coffee by name or a tablet taken the wrong way. This page does not suggest doses beyond the label's schedule.
Sources
- WEGOVY (semaglutide) prescribing information, NDA 215256/S-025, revised June 2026. U.S. Food and Drug Administration; sections 1, 2, 5, 6, 7, 8, 11, 12.3, 14.2, 16 and 17. accessdata.fda.gov
- Novo Nordisk. NovoCare: Price your Wegovy, including self-pay and commercial insurance prices and the list price. Read November 20, 2026. novocare.com
Related analyses
Missed a dose of Zepbound or Wegovy? The label rule, checked against your dates
Wegovy side effects: how common each one is, when it peaks and how long it lasts
Mounjaro side effects: how common each one is by dose, and when they ease
Ozempic side effects: how common each one is by dose, and when they ease
Log each tablet and the time you ate, and keep the morning routine on track.
Open Dose Insider